ReviewFrontiers in neurology2025
Prognostic value of lymphocyte-to-monocyte ratio in acute ischemic stroke: a systematic review and meta-analysis.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Serum sCD163 as a potential biomarker for predicting poor functional outcome at 3 months in acute ischemic stroke without reperfusion: a prospective study.Frontiers in immunology · 2026Article
- The Ratio Paradox in Stroke Prognosis: Abundant Evidence, Absent Utility.Translational stroke research · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The findings from studies exploring the prognostic relevance of the lymphocyte-to-monocyte ratio (LMR) in individuals with acute ischemic stroke (AIS) have shown variability. We aimed to conduct a meta-analysis to determine the prognostic significance of LMR in this patient population. Methods: We carried out a meta-analysis utilizing information from major databases, including PubMed, Embase, and Web of Science until October 26, 2024. Effect sizes, represented as odds ratios (ORs) along with their corresponding 95% confidence intervals (CI), were synthesized employing a random-effects model in Review Manager Version 5.4. To investigate possible sources of variability, we conducted subgroup analyses. Additionally, publication bias was assessed through the use of a funnel plot. Poor functional outcome at 3 months, as indicated via a modified Rankin Scale score of ≥3, was the main outcome. A moderate to severe stroke, determined by a National Institutes of Health Stroke Scale score of ≥6, was the secondary outcome. Results: Six trials totaling 1,225 individuals were included in our analysis. In AIS patients, we discovered a significant correlation between lower LMR and poorer functional outcome at 3 months, with an OR of 0.63, 95% CI of 0.49 to 0.80, and a Conclusion: This meta-analysis indicated that LMR was a prognostic factor for clinical outcomes in AIS patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.